|RFx ID :||25424268|
|Tender Name :||Future Procurement Opportunity (FPO) – Supply of non-injectable testosterone product|
|Reference # :|
|Open Date :||Q1 2022|
|Indicative RFx Release Date :||Q2 2022 [?]|
|Tender Type :||Future Procurement Opportunity (FPO)|
|Project Status :||Initial development [?]|
|Indicative Total Value :||$500K - $1M [?]|
|Expected number of contracts offered :||1|
|Required Pre-qualifications :||None|
Pharmac Procurement Team
The supplier of testosterone undecanoate capsules (current brand Andriol Testocaps) has notified of a product discontinuation. Testosterone undecanoate capsules have been listed on the Pharmaceutical Schedule since 1994. Testosterone undecanoate capsules are being discontinued, with current stock expected to be exhausted in 2022.
To date, Pharmac has been unable to source an alternative supply of oral testosterone for the New Zealand market. Therefore, Pharmac is considering issuing a competitive process for supply of a non-injectable testosterone product. For example, this could be an oral or a topical product. Pharmac is considering listing one or more topical testosterone products, in addition to the currently funded patches and injections, without funding restrictions, subject to competitive pricing compared to the currently funded testosterone products. Pharmac may consider listing more than one new presentation.
In the year ending 30 June 2021, approximately 600,000 testosterone undecanoate 40 mg capsules were dispensed to 810 people. Total expenditure over the 2021 financial year was approximately $210,000. Total expenditure for the testosterone market over the 2021 financial year was approximately $2,078,000.
Subscribe to this FPO to access additional information, including more testosterone market information.